Tom Moens
@tmoens.bsky.social
Postdoc CRUK Scotland Institute. Interested in neurons, neurofibromatosis, neurodegeneration, other stuff
Reposted by Tom Moens
First post here! Our latest paper showing CRISPR-CasRx can target both sense and antisense C9orf72 repeats is just out! rdcu.be/d5ADQ co-led by @alexcammack.bsky.social @ukdri.bsky.social @uclqsion.bsky.social
Dual-targeting CRISPR-CasRx reduces C9orf72 ALS/FTD sense and antisense repeat RNAs in vitro and in vivo
Nature Communications - CRISPR-CasRx effectively reduces ALS- and FTD-causing C9orf72 sense and antisense repeat derived RNAs and proteins in cell lines, patient iPSC-neurons and two independent...
rdcu.be
January 8, 2025 at 11:41 AM
First post here! Our latest paper showing CRISPR-CasRx can target both sense and antisense C9orf72 repeats is just out! rdcu.be/d5ADQ co-led by @alexcammack.bsky.social @ukdri.bsky.social @uclqsion.bsky.social